The extreme environments within the biosphere are inhabited by organisms known as extremophiles. In recent years to Lately, these organisms are attracting a great deal of interest from researchers and industrialists. The motive behind this attraction is mainly related to the desire for new and efficient products of biotechnological importance and human curiosity of understanding nature.
Organisms living in common “human-friendly” environments have served humanity for a very long time, and this has led to exhaustion of the low-hanging “fruits,” a phenomenon witnessed by the diminishing rate of new discoveries.
In recent times by For example, acquiring novel products such as drugs from the traditional sources has become difficult and expensive. Such challenges together with the basic research interest have brought the exploration of previously neglected or unknown groups of organisms.
Extremophiles are among these groups which have been brought to focus and garnering a growing importance in biotechnology. In the last few decades, numerous extremophiles and their products have got their ways into industrial, agricultural, environmental, pharmaceutical, and other biotechnological applications.Alkaliphiles, organisms which thrive optimally at or above pH 9, are one of the most important classes of extremophiles. To flourish in their extreme habitats, alkaliphiles evolved impressive structural and functional adaptations.
ASAP1 antibody Antibody |
DF8746 |
Affbiotech |
200ul |
EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
LSMab09882 |
Lifescience Market |
100 ug |
EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
F54788-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
F54788-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 379 |
Antibody |
A1360-500 |
Biovision |
each |
Ask for price |
Anti-Glycolipid Antibody (AGA) Antibody |
20-abx004855 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx008109 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx123734 |
Abbexa |
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx014333 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx033330-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx033330-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Anti-Glycolipid Antibody (AGA) Antibody |
abx036399-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319900 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319901 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319905 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319913 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
abx230204-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx324434 |
Abbexa |
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx311665 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx234901-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
Anti-Anti-SEPT6 antibody antibody |
STJ11100949 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
STJ111369 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT4 Antibody antibody |
STJ112276 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-SEPT5 Antibody antibody |
STJ114819 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT7 Antibody antibody |
STJ116214 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
STJ117206 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT12 Antibody antibody |
STJ117759 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT7 Antibody antibody |
STJ28963 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT5 Antibody antibody |
STJ25477 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
STJ25479 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT1 antibody antibody |
STJ119580 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
CLCN5 Antibody / CIC-5 antibody |
RQ6462 |
NSJ Bioreagents |
100ug |
EUR 419 |
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
48169-100ul |
SAB |
100ul |
EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
48169-50ul |
SAB |
50ul |
EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
065-A-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
065-A-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
Antibody Pair to ApoA-V antibody |
10R-1876 |
Fitzgerald |
100 ul |
EUR 781.2 |
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103034 |
Abbexa |
-
EUR 543.60
-
EUR 159.60
-
EUR 1562.40
-
EUR 744.00
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103035 |
Abbexa |
-
EUR 560.40
-
EUR 159.60
-
EUR 1612.80
-
EUR 760.80
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103036 |
Abbexa |
-
EUR 577.20
-
EUR 159.60
-
EUR 1696.80
-
EUR 794.40
-
EUR 427.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
abx023924-1mg |
Abbexa |
1 mg |
EUR 1446 |
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319902 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319903 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319904 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319906 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319907 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319908 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319914 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319915 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319916 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319929 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319930 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319931 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
20-abx311666 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
20-abx311667 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
20-abx311668 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
abx233571-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
abx411057-50ug |
Abbexa |
50 ug |
EUR 710.4 |
|
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
AMM06679G |
Leading Biology |
0.05mg |
EUR 633.6 |
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
Goat anti- human Antibody^Polyclonal antibody |
LSMab09896 |
Lifescience Market |
100 ug |
EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
SPC-692D |
Stressmarq |
0.1mg |
EUR 424.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A390 |
Stressmarq |
0.1mg |
EUR 481.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A488 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A565 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A594 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A633 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A655 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A680 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A700 |
Stressmarq |
0.1mg |
EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-ALP |
Stressmarq |
0.1mg |
EUR 472.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-APC |
Stressmarq |
0.1mg |
EUR 478.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-APCCY7 |
Stressmarq |
0.1mg |
EUR 565.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-BI |
Stressmarq |
0.1mg |
EUR 475.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY350 |
Stressmarq |
0.1mg |
EUR 496.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY405 |
Stressmarq |
0.1mg |
EUR 483.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY488 |
Stressmarq |
0.1mg |
EUR 471.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY594 |
Stressmarq |
0.1mg |
EUR 474 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY633 |
Stressmarq |
0.1mg |
EUR 468 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-FITC |
Stressmarq |
0.1mg |
EUR 470.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-HRP |
Stressmarq |
0.1mg |
EUR 465.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-P594 |
Stressmarq |
0.1mg |
EUR 488.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-PCP |
Stressmarq |
0.1mg |
EUR 478.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-RPE |
Stressmarq |
0.1mg |
EUR 476.4 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-STR |
Stressmarq |
0.1mg |
EUR 477.6 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
Antibody for Human alpha Tubulin Antibody |
SPC-692S |
Stressmarq |
0.012mg |
EUR 78 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Lambda Light Chain Antibody / Lambda Antibody |
R20161-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20161BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20161SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
R20179-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20179BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
R20179SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
RQ4975 |
NSJ Bioreagents |
100ul |
EUR 419 |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Aggrecan antibody |
61-1049 |
Fitzgerald |
250 ug |
EUR 457.2 |
Description: Mouse Monoclonal Aggrecan antibody (Biotin) |
Calcitonin antibody |
61-1050 |
Fitzgerald |
500 ug |
EUR 600 |
Description: Mouse Monoclonal Calcitonin antibody (Biotin) |
HCG antibody |
61-1052 |
Fitzgerald |
500 ug |
EUR 457.2 |
Description: Mouse Monoclonal HCG antibody (Biotin) |
Osteocalcin antibody |
61-1056 |
Fitzgerald |
250 ug |
EUR 457.2 |
Description: Mouse Monoclonal Osteocalcin antibody (Biotin) |
ZIP12 Antibody |
6101-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: ZIP12 Antibody: The zinc transporter ZIP12, also known as SLC39A12, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP12 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Increased levels of ZIP12 have been observed during acute inflammation in the airway and asthma, suggesting that it may be promote increased zinc uptake, as this can reduce inflammation. The zinc content in brains in individuals with schizophrenia is lower than in individuals with other cerebral diseases, and mutations in ZIP12 have been observed in a small group of schizophrenic patients, suggesting that ZIP12 may play a role in this disease. |
ZIP12 Antibody |
6101-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: ZIP12 Antibody: The zinc transporter ZIP12, also known as SLC39A12, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP12 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Increased levels of ZIP12 have been observed during acute inflammation in the airway and asthma, suggesting that it may be promote increased zinc uptake, as this can reduce inflammation. The zinc content in brains in individuals with schizophrenia is lower than in individuals with other cerebral diseases, and mutations in ZIP12 have been observed in a small group of schizophrenic patients, suggesting that ZIP12 may play a role in this disease. |
ZIP13 Antibody |
6103-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: ZIP13 Antibody: The zinc transporter ZIP13, also known as SLC39A13, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP13 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Mutations in ZIP13 have recently been shown to cause a spondylocheiro dysplastic form of Ehlers-Danlos syndrome (SCD-EDS), a generalized skeletal dysplasia involving mainly the spine with clinical abnormalities of the hands in addition to EDS-like features. Other experiments have shown that ZIP13 is required for proper connective tissue development and is involved in BMP/TGF- signaling pathways. |
ZIP13 Antibody |
6103-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: ZIP13 Antibody: The zinc transporter ZIP13, also known as SLC39A13, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP13 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Mutations in ZIP13 have recently been shown to cause a spondylocheiro dysplastic form of Ehlers-Danlos syndrome (SCD-EDS), a generalized skeletal dysplasia involving mainly the spine with clinical abnormalities of the hands in addition to EDS-like features. Other experiments have shown that ZIP13 is required for proper connective tissue development and is involved in BMP/TGF- signaling pathways. |
ZIP14 Antibody |
6105-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: ZIP14 Antibody: The zinc transporter ZIP14, also known as SLC39A14, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP14 is a glycosylated multipass plasma membrane protein that belongs to the ZIP transporter subfamily LIV-1. ZIP14 has been shown to contribute to the hypozincemia of inflammation and infection and is regulated in the liver by IL-6. In addition to zinc, ZIP14 is also involved in the cellular uptake of non-transferrin-bound iron as well as iron bound to transferrin. |
ZIP14 Antibody |
6105-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: ZIP14 Antibody: The zinc transporter ZIP14, also known as SLC39A14, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP14 is a glycosylated multipass plasma membrane protein that belongs to the ZIP transporter subfamily LIV-1. ZIP14 has been shown to contribute to the hypozincemia of inflammation and infection and is regulated in the liver by IL-6. In addition to zinc, ZIP14 is also involved in the cellular uptake of non-transferrin-bound iron as well as iron bound to transferrin. |
KLOTHO Antibody |
6107-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: KLOTHO Antibody: KLOTHO is the systemic anti-aging hormone within the glycosidase1 superfamily. It encodes a type I membrane protein that is abundant in the kidney and brain. In mice, a deficiency in KLOTHO expression leads to various systemic phenotypes resembling human aging such as arteriosclerosis, osteoporosis, and skin atrophy together with growth retardation, short life-span and infertility. Transgenic mice overexpressing KLOTHO have an extended life span by inhibiting insulin/IGF1 signaling. KLOTHO is involved in the regulation of calcium/phosphorus homeostasis by inhibiting the synthesis of active vitamin D and identified as a potential tumor suppressor. |
KLOTHO Antibody |
6107-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: KLOTHO Antibody: KLOTHO is the systemic anti-aging hormone within the glycosidase1 superfamily. It encodes a type I membrane protein that is abundant in the kidney and brain. In mice, a deficiency in KLOTHO expression leads to various systemic phenotypes resembling human aging such as arteriosclerosis, osteoporosis, and skin atrophy together with growth retardation, short life-span and infertility. Transgenic mice overexpressing KLOTHO have an extended life span by inhibiting insulin/IGF1 signaling. KLOTHO is involved in the regulation of calcium/phosphorus homeostasis by inhibiting the synthesis of active vitamin D and identified as a potential tumor suppressor. |
REQUIEM Antibody |
6109-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: REQUIEM Antibody: Requiem is a member of the d4 domain family, characterized by a zinc finger-like structural motif. This protein functions as a transcription factor which is necessary for the apoptotic response following deprivation of survival factors. It is expressed in numerous tissues in both cytosolic and nuclear regions and likely serves a regulatory role in rapid hematopoietic cell growth and turnover. Requiem has been found to act as an adaptor protein that links the NF-κB and SWI/SNF chromatin remodeling factor and is considered a candidate gene for multiple endocrine neoplasia type I, an inherited cancer syndrome involving multiple parathyroid, enteropancreatic, and pituitary tumors. |
REQUIEM Antibody |
6109-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: REQUIEM Antibody: Requiem is a member of the d4 domain family, characterized by a zinc finger-like structural motif. This protein functions as a transcription factor which is necessary for the apoptotic response following deprivation of survival factors. It is expressed in numerous tissues in both cytosolic and nuclear regions and likely serves a regulatory role in rapid hematopoietic cell growth and turnover. Requiem has been found to act as an adaptor protein that links the NF-κB and SWI/SNF chromatin remodeling factor and is considered a candidate gene for multiple endocrine neoplasia type I, an inherited cancer syndrome involving multiple parathyroid, enteropancreatic, and pituitary tumors. |
CXXC5 Antibody |
6111-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: CXXC5 Antibody: CXXC5 is zinc finger protein closely related to the DVL1-binding protein CXXC4 (also known as Idax), and like CXXC4 is thought to modulate the Wnt signaling pathway during development. CXXC5 is upregulated in neural stem cells upon BMP4 stimulation, leading to decreased levels of the Wnt-signaling target AXIN2 and facilitated the response of the stem cells to Wnt3a. Recent reports suggest CXXC5 transcription is activated by the Wilms tumor 1 (WT1) transcription factor, and together are involved in the WNT/beta-catenin pathway and play a role in embryonic kidney development. |
CXXC5 Antibody |
6111-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: CXXC5 Antibody: CXXC5 is zinc finger protein closely related to the DVL1-binding protein CXXC4 (also known as Idax), and like CXXC4 is thought to modulate the Wnt signaling pathway during development. CXXC5 is upregulated in neural stem cells upon BMP4 stimulation, leading to decreased levels of the Wnt-signaling target AXIN2 and facilitated the response of the stem cells to Wnt3a. Recent reports suggest CXXC5 transcription is activated by the Wilms tumor 1 (WT1) transcription factor, and together are involved in the WNT/beta-catenin pathway and play a role in embryonic kidney development. |
TFF3 Antibody |
6113-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: TFF3 Antibody: Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. Trefoil peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain and clustered in human chromosome 21q22.3. Trefoil Factor 3 (TFF3) is one of three trefoil peptides secreted by epithelial cells that line mucus membranes in the large and small intestines and lower respiratory tract. TFF3 is mainly active as a disulfide-linked homodimer and may have a role in promoting cell migration in healing processes. It is involved in the maintenance and repair of the intestinal mucosa. |
TFF3 Antibody |
6113-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: TFF3 Antibody: Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. Trefoil peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain and clustered in human chromosome 21q22.3. Trefoil Factor 3 (TFF3) is one of three trefoil peptides secreted by epithelial cells that line mucus membranes in the large and small intestines and lower respiratory tract. TFF3 is mainly active as a disulfide-linked homodimer and may have a role in promoting cell migration in healing processes. It is involved in the maintenance and repair of the intestinal mucosa. |
The high pH adaptation gave unique biocatalysts that are operationally stable at elevated pH and several other novel products with immense biotechnological application potential. Advances in the cultivation techniques, success in gene cloning and expression, metabolic engineering, metagenomics, and other related techniques are significantly contributing to expand the application horizon of these remarkable organisms of the ‘bizarre’ world. Studies have shown the enormous potential of alkaliphiles in numerous biotechnological applications. Although it seems just the beginning, some fantastic strides are already made in tapping this potential.
This work tries to review some of the prominent applications of alkaliphiles by focusing such as on their enzymes, metabolites, exopolysaccharides, and biosurfactants. Moreover, the chapter strives to assesses the whole-cell applications of alkaliphiles including in biomining, food and feed supplementation, bioconstruction, microbial fuel cell, biofuel production, and bioremediation.